Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient
Sineida Berbert Ferreira, Rachel Berbert Ferreira, Afonso Cesar Neves Neto, Silvana Martins Caparroz‐Assef, Morton Scheinberg
Abstract
Vitiligo is an autoimmune skin disease presenting with areas of depigmentation. Recent reports suggest that Janus kinase (JAK) inhibitors may be an effective therapy. In this case report, we show our experience with an adolescent patient with a long history of generalized and refractory vitiligo, for which treatment with topical tofacitinib, a JAK inhibitor, associated with phototherapy for 9 months, resulted in near complete repigmentation.
Topics & Concepts
TofacitinibVitiligoMedicineDepigmentationJanus kinase inhibitorJanus kinaseDermatologyRefractory (planetary science)PsoriasisImmunologyAstrobiologyCytokinePhysicsRheumatoid arthritismelanin and skin pigmentationSkin Protection and AgingMast cells and histamine